Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver Congress 2025

Published: 2025-05-08 11:35:50 ET ABUS

Published on 05/08/2025 at 11:35

WARMINSTER - Arbutus Biopharma Corporation (Nasdaq: ABUS) ('Arbutus' or the 'Company'), a clinical-stage biopharmaceutical company focused on infectious disease, announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi therapeutic and AB-101, its oral PD-L1 inhibitor, at the European Association for the Study of the Liver (EASL) Congress 2025.

In a late-breaker poster presentation, the following select key end-of-study data were reported from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) evaluating stable nucleos(t)ide analogue (NA) therapy throughout the treatment period with imdusiran (60mg every 8 weeks) for 24 weeks and either Barinthus Biotherapeutic's T-cell stimulating immunotherapeutic VTP-300 without nivolumab (Group A, n=20) or with low dose nivolumab (Group C, n=22; 13 received nivolumab) or placebo (Group B, n=20): Three patients in Group C with the addition of nivolumab had HBsAg loss (HBsAg